Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women

References

• Bretelle F, Sabatier F, Blann A, D’Ercole C, Boutière B, Mutin M, Boubli L, et al. Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: comparison with pre-eclampsia. BJOG 2001;108:1277–1282.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003;69:1–7.
   PubMed Web of Science ®Google Scholar
• Toft JH, Lian IA, Tarca AL, Erez O, Espinoza J, Eide IP, Bjørge L, et al. Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies. J Matern Fetal Neonatal Med 2008;21:267–273.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Gotsch F, Espinoza J, Nien JK, Goncalves L, Edwin S, et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 2008;21:41–52.
   PubMed Web of Science ®Google Scholar
• Laskowska M, Laskowska K, Leszczynska-Gorzelak B, Oleszczuk J. Are the maternal and umbilical VEGF-A and SVEGF-R1 altered in pregnancies complicated by preeclampsia with or without intrauterine foetal growth retardation? Preliminary communication. Med Wieku Rozwoj 2008;12:499–506.
   PubMedGoogle Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–658.
   PubMed Web of Science ®Google Scholar
• Marsál K. Intrauterine growth restriction. Curr Opin Obstet Gynecol 2002;14:127–135.
   PubMed Web of Science ®Google Scholar
• Robinson JS, Owens JA. Pathophysiology of intrauterine growth failure. In: Gluckman PD, Heymann MA, editors. Pediatrics and Perinatology: The Scientific Basis. London: Arnold. 1996:290–297.
   Google Scholar
• Ruebner M, Strissel PL, Langbein M, Fahlbusch F, Wachter DL, Faschingbauer F, Beckmann MW, Strick R. Impaired cell fusion and differentiation in placentae from patients with intrauterine growth restriction correlate with reduced levels of HERV envelope genes. J Mol Med 2010;88:1143–1156.
   PubMedGoogle Scholar
• Mayhew TM, Ohadike C, Baker PN, Crocker IP, Mitchell C, Ong SS. Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. Placenta 2003;24:219–226.
   PubMed Web of Science ®Google Scholar
• Maulik D, Frances Evans J, Ragolia L. Fetal growth restriction: pathogenic mechanisms. Clin Obstet Gynecol 2006;49:219–227.
   PubMed Web of Science ®Google Scholar
• Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci 2007;112:51–57.
   PubMed Web of Science ®Google Scholar
• Briana DD, Malamitsi-Puchner A. Intrauterine growth restriction and adult disease: the role of adipocytokines. Eur J Endocrinol 2009;160:337–347.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
   PubMed Web of Science ®Google Scholar
• Wulff C, Weigand M, Kreienberg R, Fraser HM. Angiogenesis during primate placentation in health and disease. Reproduction 2003;126:569–577.
   PubMed Web of Science ®Google Scholar
• Smith SK, He Y, Clark DE, Charnock-Jones DS. Angiogenic growth factor expression in placenta. Semin Perinatol 2000;24:82–86.
   PubMed Web of Science ®Google Scholar
• Robinson ChJ Johnson, DD. Soluble endoglin as a second – trimester marker for preeclampsia. Am J Obstet Gynecol 2007;197:174e1–174e5
   Google Scholar
• Smith GC, Wear H. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 2009;21:111–116.
   PubMed Web of Science ®Google Scholar
• Ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. DOI 2008;10.1007/s10456-008:9101-9
   Google Scholar
• Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A, Boileau C, Allanore Y. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 2008;47:972–975.
   PubMed Web of Science ®Google Scholar
• Fujishita A, Hasuo A, Khan KN, Masuzaki H, Nakashima H, Ishimaru T. Immunohistochemical study of angiogenic factors in endometrium and endometriosis. Gynecol Obstet Invest 1999;48 Suppl 1:36–44.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–649.
   PubMed Web of Science ®Google Scholar
• Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T, Post M, Caniggia I. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008;172:77–85.
   PubMed Web of Science ®Google Scholar
• Maharaj AS, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, Matharu KS, et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008;205:491–501.
   PubMed Web of Science ®Google Scholar
• Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006;21:3052–3054.
   PubMed Web of Science ®Google Scholar
• Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract 2007;106:c72–c81.
   PubMedGoogle Scholar
• Mandruzzato G, Antsaklis A, Botet F, Chervenak FA, Figueras F, Grunebaum A, Puerto B, et al.; WAPM. Intrauterine restriction (IUGR). J Perinat Med 2008;36:277–281.
   PubMed Web of Science ®Google Scholar
• Stepan H, Krämer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007;92:2831–2834.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992–1005.
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23.
   PubMed Web of Science ®Google Scholar
• Stepan H, Jank A. [Angiogenic factors and their role in pathogenesis and prediction of preeclampsia]. Z Geburtshilfe Neonatol 2009;213:101–105.
   PubMedGoogle Scholar
• McCarthy C, Cotter FE, McElwaine S, Twomey A, Mooney EE, Ryan F, Vaughan J. Altered gene expression patterns in intrauterine growth restriction: potential role of hypoxia. Am J Obstet Gynecol 2007;196:70.e1–70.e6.
   Google Scholar
• Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279–287.
   PubMed Web of Science ®Google Scholar
• Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008;29:555–563.
   PubMed Web of Science ®Google Scholar
• Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008;93:260–266.
   PubMed Web of Science ®Google Scholar
• Reddy A, Suri S, Sargent IL, Redman ChWG, Muttukrishna S. Materna cirtculating levels of activin A, Inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and preeclampsia. PLoS One 2009;2,2:44–53
   Google Scholar
• Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007;92:2672–2679.
   PubMed Web of Science ®Google Scholar
• Purwosunu Y, Sekizawa A, Farina A, Wibowo N, Koide K, Okazaki S, Nakamura M, Okai T. Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors. Am J Obstet Gynecol 2008;198:124.e1–124.e7.
   Google Scholar
• Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia–a step forward but not the definitive answer. J Reprod Immunol 2009;82:106–111.
   PubMed Web of Science ®Google Scholar